Northwest Biotherapeutics (NWBO) EBIAT: 2009-2025
Historic EBIAT for Northwest Biotherapeutics (NWBO) over the last 17 years, with Sep 2025 value amounting to -$26.8 million.
- Northwest Biotherapeutics' EBIAT fell 38.48% to -$26.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$89.8 million, marking a year-over-year decrease of 29.11%. This contributed to the annual value of -$83.8 million for FY2024, which is 33.83% down from last year.
- As of Q3 2025, Northwest Biotherapeutics' EBIAT stood at -$26.8 million, which was down 74.46% from -$15.4 million recorded in Q2 2025.
- In the past 5 years, Northwest Biotherapeutics' EBIAT registered a high of $133.3 million during Q4 2021, and its lowest value of -$32.9 million during Q3 2022.
- In the last 3 years, Northwest Biotherapeutics' EBIAT had a median value of -$18.3 million in 2024 and averaged -$18.9 million.
- Its EBIAT has fluctuated over the past 5 years, first spiked by 147.56% in 2021, then plummeted by 772.74% in 2022.
- Northwest Biotherapeutics' EBIAT (Quarterly) stood at $133.3 million in 2021, then plummeted by 121.23% to -$28.3 million in 2022, then surged by 50.61% to -$14.0 million in 2023, then crashed by 101.92% to -$28.2 million in 2024, then tumbled by 38.48% to -$26.8 million in 2025.
- Its EBIAT stands at -$26.8 million for Q3 2025, versus -$15.4 million for Q2 2025 and -$19.3 million for Q1 2025.